PE20040158A1 - Sales de nateglinida - Google Patents

Sales de nateglinida

Info

Publication number
PE20040158A1
PE20040158A1 PE2003000246A PE2003000246A PE20040158A1 PE 20040158 A1 PE20040158 A1 PE 20040158A1 PE 2003000246 A PE2003000246 A PE 2003000246A PE 2003000246 A PE2003000246 A PE 2003000246A PE 20040158 A1 PE20040158 A1 PE 20040158A1
Authority
PE
Peru
Prior art keywords
inhibitors
nateglinide
protonated form
angiatidethe
refers
Prior art date
Application number
PE2003000246A
Other languages
English (en)
Spanish (es)
Inventor
La Cruz Marilyn De
Richard Victor Vivilecchia
Paul Allen Sutton
David John Parker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040158A1 publication Critical patent/PE20040158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2003000246A 2002-03-11 2003-03-11 Sales de nateglinida PE20040158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36317802P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
PE20040158A1 true PE20040158A1 (es) 2004-04-26

Family

ID=27805267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000246A PE20040158A1 (es) 2002-03-11 2003-03-11 Sales de nateglinida

Country Status (11)

Country Link
US (2) US20050234129A1 (https=)
EP (1) EP1483232A1 (https=)
JP (2) JP2005519949A (https=)
CN (1) CN1274668C (https=)
AR (1) AR038927A1 (https=)
AU (1) AU2003214112A1 (https=)
BR (1) BR0308316A (https=)
CA (1) CA2478599A1 (https=)
PE (1) PE20040158A1 (https=)
TW (1) TW200304813A (https=)
WO (1) WO2003076393A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1616886A4 (en) * 2003-02-18 2006-06-14 Konishi Co Ltd CURABLE RESIN, PROCESS FOR PRODUCING THE SAME, AND CURABLE RESIN COMPOSITION
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005016315A1 (en) * 2003-08-14 2005-02-24 Ranbaxy Laboratories Limited Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
TWI340650B (en) 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
KR20070009726A (ko) * 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2305239A1 (fr) * 2009-09-24 2011-04-06 Assistance Publique, Hopitaux De Paris Neuroprotection retinienne par des inhibiteurs des canaux ioniques regules par la sous-unite SUR
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
CN103417971A (zh) * 2013-08-13 2013-12-04 深圳奥萨医药有限公司 二肽基肽酶抑制剂和b族维生素的药物组合物及用途
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP1167346A4 (en) * 1999-04-06 2003-07-23 Ono Pharmaceutical Co DERIVATIVES OF 4-AMINOBUTANIC ACID AND MEDICINES THAT CONTAIN THESE DERIVATIVES AS ACTIVE ACTIVE SUBSTANCES
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
CA2393083C (en) * 1999-12-23 2010-01-26 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)

Also Published As

Publication number Publication date
JP2011006476A (ja) 2011-01-13
EP1483232A1 (en) 2004-12-08
US20090143469A1 (en) 2009-06-04
CN1274668C (zh) 2006-09-13
AU2003214112A1 (en) 2003-09-22
WO2003076393A1 (en) 2003-09-18
BR0308316A (pt) 2004-12-28
JP2005519949A (ja) 2005-07-07
CN1642904A (zh) 2005-07-20
US20050234129A1 (en) 2005-10-20
TW200304813A (en) 2003-10-16
AR038927A1 (es) 2005-02-02
CA2478599A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
PE20040158A1 (es) Sales de nateglinida
ES2636692T3 (es) Formulación de anticuerpos humanos para tratar trastornos asociados con TNF-alfa
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
UY29759A1 (es) Formulaciones de ibandronato mejoradas
PE20151205A1 (es) Formulaciones que contienen linaclotida para administracion oral
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
PE20081578A1 (es) Formulacion en polvo de valganciclovir
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
JP2005519949A5 (https=)
AR054448A1 (es) Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis
AR029412A1 (es) Forma cristalina
MXPA05004377A (es) Composiciones inyectables no dolorosas que contienen sales de los acidos 2-arilpropionico.
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
NO20082181L (no) Formuleringer av Fispemifen
ES2219633T3 (es) Sal de creatina que tiene eficacia nutricional y terapeutica y composiciones que la contienen.
US20070088086A1 (en) Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
Pokrovskii et al. Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide defi ciency
PE20040724A1 (es) Composicion para la administracion oral de calcitonina
PE20060460A1 (es) Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral
HN2003000015A (es) Sales estables del acido o acetilsalicilico con aminoacidos basicos i i.
AR044802A1 (es) Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos
UY30471A1 (es) Formulacion de medicamento acuosa del de acido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenetil}-amino)metil]benzoico
PE20170136A1 (es) Combinacion de un aine y un aminoacido

Legal Events

Date Code Title Description
FD Application declared void or lapsed